Mirko Scarsi1, Tamara Ziglioli, Paolo Airo'. 1. Rheumatology and Clinical Immunology Service, Spedali Civili di Brescia, piazzale Spedali Civili 1, 25123 Brescia, Italy.
Abstract
OBJECTIVE: To evaluate the number of circulating CD28-negative (CD28-) T cells as a predictor of clinical response to abatacept in patients with rheumatoid arthritis (RA). METHODS: Peripheral blood CD28- T cell subsets were evaluated by flow cytometry at baseline in 32 patients with RA treated with abatacept. Receiver-operator curves were applied to examine the predictive value of T cell populations and to choose the cutoff for the best performance of the test. Remission was defined using the Disease Activity Score 28 based on C-reactive protein. RESULTS: The overall predictive values of the CD8+CD28- and CD4+CD28- cells for remission after 6 months of abatacept therapy were 0.802 (SE 0.078) and 0.743 (SE 0.089), respectively. Cutoff values of < 87 CD8+CD28- cells/μl and < 28 CD4+CD28- cells/μl had 80.0% sensitivity and 81.8% specificity (Fisher test: p = 0.001), and 60.0% sensitivity and 77.3% specificity (p = 0.043), respectively, for prediction of remission at 6 months. Patients having low baseline numbers of CD8+CD28- T cells had a more than 4-fold higher probability of achieving remission within 6 months than patients with higher levels of these cells. CONCLUSION: A simple laboratory measure, the baseline number of circulating CD28- T cells, predicted remission after 6 months of abatacept treatment in patients with RA.
OBJECTIVE: To evaluate the number of circulating CD28-negative (CD28-) T cells as a predictor of clinical response to abatacept in patients with rheumatoid arthritis (RA). METHODS: Peripheral blood CD28- T cell subsets were evaluated by flow cytometry at baseline in 32 patients with RA treated with abatacept. Receiver-operator curves were applied to examine the predictive value of T cell populations and to choose the cutoff for the best performance of the test. Remission was defined using the Disease Activity Score 28 based on C-reactive protein. RESULTS: The overall predictive values of the CD8+CD28- and CD4+CD28- cells for remission after 6 months of abatacept therapy were 0.802 (SE 0.078) and 0.743 (SE 0.089), respectively. Cutoff values of < 87 CD8+CD28- cells/μl and < 28 CD4+CD28- cells/μl had 80.0% sensitivity and 81.8% specificity (Fisher test: p = 0.001), and 60.0% sensitivity and 77.3% specificity (p = 0.043), respectively, for prediction of remission at 6 months. Patients having low baseline numbers of CD8+CD28- T cells had a more than 4-fold higher probability of achieving remission within 6 months than patients with higher levels of these cells. CONCLUSION: A simple laboratory measure, the baseline number of circulating CD28- T cells, predicted remission after 6 months of abatacept treatment in patients with RA.
Authors: Joerg Ermann; Deepak A Rao; Nikola C Teslovich; Michael B Brenner; Soumya Raychaudhuri Journal: Nat Rev Rheumatol Date: 2015-06-02 Impact factor: 20.543
Authors: Amit D Parulekar; Jonathan S Boomer; Brenda M Patterson; Huiqing Yin-Declue; Christine M Deppong; Brad S Wilson; Nizar N Jarjour; Mario Castro; Jonathan M Green Journal: Am J Respir Crit Care Med Date: 2013-01-04 Impact factor: 21.405
Authors: A Picchianti Diamanti; M M Rosado; M Scarsella; V Germano; E Giorda; S Cascioli; B Laganà; R D'Amelio; R Carsetti Journal: Clin Exp Immunol Date: 2014-09 Impact factor: 4.330
Authors: Hubert G Nüßlein; Rieke Alten; Mauro Galeazzi; Hanns-Martin Lorenz; Michael T Nurmohamed; William G Bensen; Gerd R Burmester; Hans-Hartmut Peter; Karel Pavelka; Melanie Chartier; Coralie Poncet; Christiane Rauch; Manuela Le Bars Journal: BMC Musculoskelet Disord Date: 2015-07-30 Impact factor: 2.362